Eduardo Vilar

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. ncbi Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona 08035, Spain
    Endocr Relat Cancer 14:221-32. 2007
  2. doi A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Ps Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Invest New Drugs 30:299-305. 2012

Detail Information

Publications2

  1. ncbi Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona 08035, Spain
    Endocr Relat Cancer 14:221-32. 2007
    ..Also a comprehensive review of the literature about chemotherapy in NETs is presented...
  2. doi A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Ps Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Invest New Drugs 30:299-305. 2012
    ..A phase I study was performed in patients with advanced solid tumors to determine the maximum tolerated dose (MTD), establish a safety profile, and to evaluate pharmacokinetics and efficacy of the drug...